Trump Administration
Refine Search
Pharmaceutical
In a world where western firms increasingly seek to ingratiate themselves with Middle Eastern leaders and investors, a Saudi company has sought to curry favor with US President Donald Trump in an announcement on pharma manufacturing. 15 May 2025
Pharmaceutical
US Department of Health and Human Services (HHS) Secretary Robert F Kennedy Jr (RFK Jr) has spoken in defence of his proposed HHS budget for fiscal year 2026 to the Senate Health, Education, Labor, and Pensions (HELP) Committee. 15 May 2025
Pharmaceutical
US President Donald Trump released an executive order on May 12 calling for a 30-day negotiation period between the Department of Health and Human Services (HHS) and the biopharma industry, with the threat of a rule from the Centers for Medicare and Medicaid Services (CMS) to lower US drug prices if no deal is reached. 14 May 2025
Pharmaceutical
US pharma stocks regained ground Monday after Donald Trump signed an executive order aiming to slash prescription drug prices, a move that initially rattled investors but left many analysts unconvinced about its impact. 13 May 2025
Pharmaceutical
US President Donald Trump sent shivers through the pharmaceutical industry as he vowed to dramatically reduce the high drug prices that have long been a feature of the US market. 12 May 2025
Pharmaceutical
UK-based pharma major AstraZeneca has started construction on a new manufacturing site for small molecule drugs in Wuxi, a city in East China's Jiangsu province, underscoring its deepening investment in the country. 12 May 2025
Pharmaceutical
The UK government has announced a trade agreement with the USA. The UK-US Economic Prosperity Deal was agreed on Thursday May 8 with further details released on Friday May 9. 9 May 2025
Pharmaceutical
UK pharma major AstraZeneca has suffered a setback in its legal fight to block the US government's efforts to lower prescription drug prices, after a federal appeals court dismissed its challenge to Medicare’s negotiation powers. 9 May 2025
Pharmaceutical
As the US government, under President Donald Trump, is on the verge of announcing significant new tariffs on pharmaceutical imports, Indian drug-maker stocks continue to take a hammering on the bourses. 8 May 2025
Pharmaceutical
Pharmaceutical and Research Manufacturers of America (PhRMA) yesterday submitted comments to the US Department of Commerce on its Section 232 investigation of pharmaceuticals and pharmaceutical ingredients imported to the USA. 8 May 2025
Pharmaceutical
US President Donald Trump has signed an executive order attempting to restore a robust domestic manufacturing base for prescription drugs in the USA. 7 May 2025
Pharmaceutical
In the USA, the Trump administration is urging congressional Republicans to include a “most favored nation” (MFN) policy in their domestic policy package that would tie Medicaid drug payments to the lowest prices paid in other wealthy countries, a White House official confirmed to Inside Health Policy. 5 May 2025
Pharmaceutical
The head of the World Health Organization has issued a stark warning that sudden cuts to global health budgets, including by the USA, are putting years of medical progress in jeopardy. 2 May 2025
Pharmaceutical
A new report from Washington DC-based group No Patient Left Behind argues that foreign governments are underestimating the value of innovative medicines — a claim that adds fuel to the ongoing transatlantic debate on drug pricing and access. 2 May 2025
Pharmaceutical
The US Department of Health and Human Services has announced a sweeping change to the way new vaccines are evaluated, saying it will now require all future vaccines to undergo testing in placebo-controlled trials before being approved for use. 2 May 2025
Pharmaceutical
Shortly after Robert F Kennedy Jr was sworn in as Secretary of Health and Human Services (HHS), US President Donald Trump issued an executive order establishing the Make America Healthy Again Commission. 1 May 2025
Pharmaceutical
AstraZeneca posted a 10% rise in first-quarter revenue to $13.6 billion, supported by strong sales of cancer drugs and biopharmaceuticals. Core earnings per share climbed 21% to $2.49, while reported EPS advanced 34% to $1.88. Pre-tax profits increased 21% year-on-year to $3.4 billion. 29 April 2025
Pharmaceutical
The USA faces a serious risk of measles becoming endemic again, according to a new study modeling the impact of declining childhood vaccination rates, published in JAMA. 28 April 2025
Pharmaceutical
The Trump administration is reportedly revisiting a contentious drug pricing strategy that would tie US medicine prices to those paid in other developed nations, according to a Reuters report citing multiple industry sources. 23 April 2025
Biotechnology
US biotech major Regeneron Pharmaceuticals has announced a significant expansion of its manufacturing capacity through a new agreement with Fujifilm Diosynth Biotechnologies to manufacture and supply bulk drug product of its commercial biologic medicines at its Holly Springs, North Carolina, campus. 22 April 2025
Pharmaceutical
Harvard University has filed a lawsuit against the US government after more than $2 billion in federal research funding was suspended, disrupting a range of biomedical and public health projects. The legal challenge, announced Monday, marks an escalation in a standoff with the Trump administration over new policy demands tied to continued grant access. 22 April 2025
Pharmaceutical
The US Department of Commerce issued a public notice announcing a “232 investigation” that is a precursor to expected tariffs on pharmaceuticals. 22 April 2025
Pharmaceutical
On the research front last week, China-based biotech Remegen released positive Phase III results for its telitacicept in myasthenia gravis. By contrast, US pharma giant Pfizer announced disappointing results for its obesity candidate danuglipron and its decision to discontinue development. Meantime, Eli Lilly’s shares leapt after it reported strong Phase III trial data on its diabetes and obesity candidate orforglipron. Additionally, there was welcome news last week for pharma companies operating in the USA, when US President Donald Trump issued an executive order calling for the scrapping of the Inflation Reduction ACT (IA) so-called pill penalty. 21 April 2025
Pharmaceutical
In keeping with US Department of Health and Human Services Secretary Robert F Kennedy Jr’s promise to carry out the Department’s work with “radical transparency” and mitigate perceived industry influence and conflicts of interests, Food and Drug Administration (FDA) Commissioner Dr Martin Makary, has announced a policy directive. 19 April 2025
Pharmaceutical
US President Donald Trump issued an executive order on April 15 listing several potential policy changes aimed at lowering US drug prices.
Responding to the announcement, Morningstar’s healthcare equity research director Karen Andersen gave her views on why this matters. 18 April 2025
Pharmaceutical
US President Donald Trump has passed an executive order that answers the pharmaceutical industry’s calls for the scrapping of the Inflation Reduction Act’s (IRA) ‘pill penalty’. 16 April 2025
Pharmaceutical
New research from consultancy Vital Transformation has shown the effects of US policy the Inflation Reduction Act’s (IRA) drug pricing provisions on biopharmaceutical investment, research and development (R&D). 15 April 2025
Biotechnology
US sequencing firm PacBio is cutting jobs and reducing spending across its business as it braces for the financial impact of new global tariffs and growing uncertainty around federal research funding. 14 April 2025
Biotechnology
Shares in US biotech Novavax fell more than 20% before the weekend, following remarks from health and human services secretary Robert F Kennedy Jr, who questioned the scientific basis of the company’s COVID-19 vaccine in a televised interview. 14 April 2025
Pharmaceutical
Speculation about the US Administration’s views on the Pharmaceutical Benefits Scheme (PBS) has reconfirmed the sanctity of the PBS as the cornerstone of Australia’s healthcare system, the domestic pharma trade group stressed. 11 April 2025
Pharmaceutical
The US Centers for Medicare & Medicaid Services (CMS) has announced action intended to preserve the core mission of the Medicaid program against a wider backdrop of wider cost-cutting under the regime of President Donald Trump. 11 April 2025
Biotechnology
Licensing agreements for Chinese drug candidates hit a record high in 2024, with large pharma in-licensing 28% of innovator drugs from Chinese biopharma companies. 9 April 2025
Biotechnology
A federal commission has urged the US government to invest $15 billion to protect the country’s leadership in biotechnology and prevent China from outpacing American innovation in the field. The warning comes amid rising concern over growing reliance on foreign manufacturing and increasing Chinese activity in licensing biotech assets. 9 April 2025
Pharmaceutical
Ireland’s government remains confident in its ability to retain the country’s strategic position in pharmaceutical manufacturing, despite rising tensions between the European Union and the United States over trade policy. 8 April 2025
Pharmaceutical
Thousands of workers dismissed from the US Department of Health and Human Services this week may soon be reinstated, after health secretary Robert F Kennedy Jr admitted that a significant share of the job cuts were made in error. 7 April 2025
Pharmaceutical
In the news last week, US Center for Biologics Evaluation and Research (CBER) Dr Peter Marks quit his post after reported pressure from a Human Health Services (HHS) official. On the research front, Merck & Co presented positive Phase III data on its Winrevair in pulmonary arterial hypertension (PAH) at the American College of Cardiology (ACC) meeting. Also, Swiss biotech AC Immune shared new Phase II data on its Parkinson’s disease candidate ACI-7104-056. Late last Wednesday, US President Donald Trump dropped a bombshell of tariffs of various amounts on countries around the world, although there was ambiguity as to how and when they would impact pharma and biotech products. 6 April 2025
Biotechnology
US biotech Novavax is still waiting on a decision from the Food and Drug Administration over full approval of its protein-based COVID-19 vaccine, despite the agency having set an April 1 target date to complete its review. 4 April 2025
Pharmaceutical
Pharmaceuticals will be exempt from the tariffs on imports to the USA that were announced by US President Donald Trump Wednesday, according to a White House fact sheet. 3 April 2025
Pharmaceutical
Freed from their former obligations to remain loyal to agency and state, a number of high-profile figures from the US Food and Drug Administration (FDA) have sounded the alarm about its direction of travel under Robert Francis Kennedy Jr (RFK Jr), the new Secretary of Health and Human Services. 2 April 2025
Pharmaceutical
The US government is reclaiming over $11 billion in unspent public health funds originally allocated during the COVID-19 emergency, a move that has drawn sharp criticism from lawmakers and public health advocates who warn it will weaken the country’s ability to respond to future health threats and disrupt essential care services. 31 March 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze